Skip to main content
. 2022 Sep 7;20(Suppl 1):S12–S21. doi: 10.1002/msc.1694

FIGURE 2.

FIGURE 2

American College of Rheumatology (ACR) 20 response rates in the major phase 3 randomised controlled trials of licenced IL‐23 blocking reagents in psoriatic arthritis (PsA). Percentages of patients achieving ACR20 at week 24, compared to placebo. The ACR20 response rates cannot be directly compared as they are derived from different studies. mg: milligrammes